To The Moon

TigerGPT Answer: ### Recursion Pharmaceuticals, Inc. (RXRX) Earnings Call Summary

#### 【Forecast Data】

- **Earnings Per Share (EPS)**:

- Forecast: -0.32 USD

- Prior Year: -0.53 USD

- **Percentage Change**: 39.62% increase

- **Significance**: The improvement in EPS indicates that the company is reducing its losses, which is a positive sign for investors.

- **Total Revenue**:

- Forecast: 24,585,710 USD

- Prior Year: 4,511,000 USD

- **Percentage Change**: 444.97% increase

- **Significance**: A significant increase in revenue suggests strong growth and potential market expansion.

- **EBIT**:

- Forecast: -140,105,830 USD

- Prior Year: -183,767,000 USD

- **Percentage Change**: 23.77% improvement

- **Significance**: The reduction in negative EBIT indicates better operational efficiency and cost management.

#### 【Quarterly Important News】

1. **Novo Holdings Divests Stake**:

- **Summary**: Novo Holdings A/S has completely divested its stake in Recursion Pharmaceuticals as of December 31, 2025.

- **Impact**: This could be seen as a lack of confidence from a major investor, potentially affecting market sentiment negatively.

2. **NVIDIA Divests Stake**:

- **Summary**: NVIDIA has also divested its stake in Recursion Pharmaceuticals, leading to a pre-market stock price drop of over 13%.

- **Impact**: Similar to Novo Holdings, this divestment could further dampen investor confidence and negatively impact the stock price.

#### 【Forecast Viewpoints】

- **Analyst Opinions**:

- Novo Holdings Divests Stake in Recursion Pharmaceuticals

- NVIDIA Divests Stake in Recursion Pharmaceuticals

#### 【Stock Trend Analysis】

- **Stock Price Fluctuation**:

- From September 30, 2025, to December 29, 2025, the stock price decreased by 15.37%.

- **Support Level**: 3.58 USD (as of February 20, 2026)

- **Resistance Level**: 3.42 USD (as of February 20, 2026)

- **Latest Price**: 3.42 USD (as of February 22, 2026)

- **Trend Analysis**: The stock is currently at a resistance level, indicating potential downward pressure. The significant drop in the past quarter suggests a bearish trend.

#### 【Options Large Order Analysis】

- **Call Options**:

- Significant volumes of call options at strike prices of 3.0, 3.5, and 4.0 USD, with both buy and sell orders.

- **Put Options**:

- Notable volumes of put options at a strike price of 3.5 USD.

- **Analysis**: The mixed activity in call and put options suggests uncertainty in the market. However, the presence of significant put options indicates a bearish sentiment, implying a higher probability of the financial report falling below expectations.

#### 【Analyst Ratings and Target Price Forecast】

- **Analyst Ratings**:

- 3 Buy, 5 Hold

- **Target Price**:

- Mean: 7.0 USD

- Low: 3.0 USD

- High: 11.0 USD

- **Valuation Status**: The current stock price of 3.42 USD is below the mean target price, suggesting the stock may be undervalued. However, the recent divestments by major investors and the bearish options activity indicate caution.

#### Comprehensive Conclusion

Recursion Pharmaceuticals, Inc. shows significant improvements in EPS and revenue, indicating positive operational performance. However, the divestments by major investors and the bearish sentiment in options trading suggest potential challenges ahead. The stock is currently undervalued based on analyst target prices, but caution is advised due to the mixed market signals.

**Disclaimer**: The above content is generated by the AI robot TigerGPT and does not represent any personal views. The content is for reference only and does not constitute any investment advice.